Abstract
The two major neuropathologic hallmarks of Alzheimers disease (AD) are extracellular Amyloid β (Aβ) plaques and intracellular neurofibrillary tangles (NFTs). A number of additional pathogenic mechanisms, possibly overlapping with Aβ plaques and NFTs formation, have been described, including inflammation, oxidative damage, iron disregulation, cholesterol metabolism. The first drugs developed for AD, anticholinesterase inhibitors (AchEI), increase acetylcholine levels, previously demonstrated to be reduced in AD. To date, four AchEI are approved for the treatment of mild to moderate AD. A further therapeutic option available for moderate to severe AD is memantine. These treatments are symptomatic, whereas drugs under development are supposed to modify pathological steps leading to AD, thus acting on the evolution of the disease. For this reason they are currently termed “disease modifying” drugs. To block the progression of the disease, they have to interfere with pathogenic steps at the basis of clinical symptoms. In this review, current treatment will be summarized and new perspectives discussed. In particular, several approaches will be described, including Aβ deposition interference by Anti-Aβ aggregation agents, vaccination, β- secretase inhibition or Selective Aβ42-lowering agents (SALAs); tau deposition interference by methyl thioninium chloride (MTC); reduction of inflammation and oxidative damage.
Keywords: Alzheimer's disease, Amyloid, tau, inflammation, disease-modifying drugs
Current Aging Science
Title: Treatment of Alzheimers Disease: Symptomatic and Disease-Modifying Approaches
Volume: 3 Issue: 1
Author(s): Daniela Galimberti and Elio Scarpini
Affiliation:
Keywords: Alzheimer's disease, Amyloid, tau, inflammation, disease-modifying drugs
Abstract: The two major neuropathologic hallmarks of Alzheimers disease (AD) are extracellular Amyloid β (Aβ) plaques and intracellular neurofibrillary tangles (NFTs). A number of additional pathogenic mechanisms, possibly overlapping with Aβ plaques and NFTs formation, have been described, including inflammation, oxidative damage, iron disregulation, cholesterol metabolism. The first drugs developed for AD, anticholinesterase inhibitors (AchEI), increase acetylcholine levels, previously demonstrated to be reduced in AD. To date, four AchEI are approved for the treatment of mild to moderate AD. A further therapeutic option available for moderate to severe AD is memantine. These treatments are symptomatic, whereas drugs under development are supposed to modify pathological steps leading to AD, thus acting on the evolution of the disease. For this reason they are currently termed “disease modifying” drugs. To block the progression of the disease, they have to interfere with pathogenic steps at the basis of clinical symptoms. In this review, current treatment will be summarized and new perspectives discussed. In particular, several approaches will be described, including Aβ deposition interference by Anti-Aβ aggregation agents, vaccination, β- secretase inhibition or Selective Aβ42-lowering agents (SALAs); tau deposition interference by methyl thioninium chloride (MTC); reduction of inflammation and oxidative damage.
Export Options
About this article
Cite this article as:
Galimberti Daniela and Scarpini Elio, Treatment of Alzheimers Disease: Symptomatic and Disease-Modifying Approaches, Current Aging Science 2010; 3 (1) . https://dx.doi.org/10.2174/1874609811003010046
DOI https://dx.doi.org/10.2174/1874609811003010046 |
Print ISSN 1874-6098 |
Publisher Name Bentham Science Publisher |
Online ISSN 1874-6128 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Assessment of Neurologic Safety Profile of Immune Checkpoint Inhibitors:
Evaluation of Adverse Drug Reaction Reports
Current Drug Safety Identification of Pyrazole Derivative as an Antiviral Agent Against Chikungunya Through HTVS
Letters in Drug Design & Discovery Current Therapeutic Options for Alzheimers Disease
Current Genomics Natural Chemical Entities as Bioactive Moiety from Weaver Ant, <i>Oecophylla smaragdina</i>: An In Vitro and In-silico Study
Letters in Drug Design & Discovery Transition-State-Guided Drug Design for Treatment of Parasitic Neglected Tropical Diseases
Current Medicinal Chemistry Improving Cognitive Outcome in Cerebral Malaria: Insights from Clinical and Experimental Research
Central Nervous System Agents in Medicinal Chemistry HIV-1, HCV and Alcohol in the CNS: Potential Interactions and Effects on Neuroinflammation
Current HIV Research Subunit Protein Vaccines: Theoretical and Practical Considerations for HIV-1
Current Molecular Medicine DHODH Hot Spots: An Underexplored Source to Guide Drug Development Efforts
Current Topics in Medicinal Chemistry Analysis of TLC-Bioautography and TLC-Spot Visualization of <i>Atropa accuminata</i> and <i>Atropa belladonna</i> Extracts as Antioxidant and Antibacterial Agents Against Human Pathogenic Bacteria
Current Pharmaceutical Analysis Research Progress of Glycyrrhizic Acid on Antiviral Activity
Mini-Reviews in Medicinal Chemistry HIV-1 Capsid Inhibitors as Antiretroviral Agents
Current HIV Research Abnormal Functional and Structural Asymmetry as Biomarker for Schizophrenia
Current Topics in Medicinal Chemistry Rationale for Peptide and DNA Based Epitope Vaccines for Alzheimers Disease Immunotherapy
CNS & Neurological Disorders - Drug Targets Alzheimers Disease and P300: Review and Evaluation of Task and Modality
Current Alzheimer Research A Review of Recent Patents on the Protozoan Parasite HSP90 as a Drug Target
Recent Patents on Biotechnology Recent Development and Future Prospects of Plant-Based Vaccines
Current Drug Metabolism Serine Protease Inhibitors and T Lymphocyte Immunity
Current Immunology Reviews (Discontinued) Childhood Infectious Encephalitis: An Overview of Clinical Features, Investigations, Treatment, and Recent Patents
Recent Patents on Inflammation & Allergy Drug Discovery Metallic Colloid Nanotechnology, Applications in Diagnosis and Therapeutics
Current Pharmaceutical Design